Bayer AG - Product Pipeline Review - 2016

Date: April 30, 2016
Pages: 250
Price:
US$ 1,500.00 US$ 1,275.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: BB6C9F04A02EN
Leaflet:

Download PDF Leaflet

Bayer AG - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Bayer AG - Product Pipeline Review - 2016’, provides an overview of the Bayer AG’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Bayer AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the pipeline therapeutic landscape of Bayer AG
  • The report provides overview of Bayer AG including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Bayer AG’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Bayer AG’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Bayer AG’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Bayer AG
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bayer AG’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Bayer AG Snapshot
Bayer AG Overview
Key Information
Key Facts
Bayer AG - Research and Development Overview
Key Therapeutic Areas
Bayer AG - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
Bayer AG - Pipeline Products Glance
Bayer AG - Late Stage Pipeline Products
Bayer AG - Clinical Stage Pipeline Products
Bayer AG - Early Stage Pipeline Products
Bayer AG - Unknown Stage Pipeline Products
Bayer AG - Drug Profiles
aflibercept
dienogest
Kovaltry
(candesartan cilexetil + nifedipine)
amikacin sulfate
ciprofloxacin hydrochloride
copanlisib hydrochloride
damoctocog alfa pegol
finerenone
nifurtimox
radium Ra 223 dichloride
regorafenib
rivaroxaban
tedizolid phosphate
(anastrozole + levonorgestrel)
anetumab ravtansine

BAY-1067197


BAY-1142524

molidustat
refametinib
riociguat
roniciclib
vericiguat
vilaprisan
sorafenib tosylate
BAY sGCstim

BAY-1082439


BAY-1093884


BAY-1112054


BAY-1125976


BAY-1128688


BAY-1129980


BAY-1143269


BAY-1143572


BAY-1161909


BAY-1163877


BAY-1179470


BAY-1187982


BAY-1213790


BAY-1214784


BAY-1217389


BAY-1251152


BAY-1862864

Drug for Diabetic Foot Ulcer
Monoclonal Antibodies for Oncology
Monoclonal Antibody Conjugate to Target CD22 for Hematological Cancers
Monoclonal Antibody for Undisclosed Indication
Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis
Small Molecule to Inhibit Activated Factor XI for Bleeding Disorders
Small Molecule to Inhibit Kinase for Inflammation and Oncology
BAY sGCact

BAY-1001931


BAY-1024767


BAY-1436032


BAY-606583

Bay-846
Immunotherapy for Oncology
Monoclonal Antibodies for Undisclosed Indication
Monoclonal Antibody to Inhibit CGEN-15001T for Oncology
Monoclonal Antibody to Inhibit CGEN-15022 for Oncology
Monocloncal Antibody Conjugate to Inhibit PDGFR-Beta Receptor for Solid Tumors
Recombinant Protein To Inhibit HER-2 Receptor for Breast Cancer
Small Molecule to Inhibit Plasminogen for Rare Bleeding Disorder
Small Molecules to Inhibit Mitogen Activated Protein Kinase Kinase for Oncology
Small Molecules to Inhibit MTH1 for Oncology
Small Molecules to Inhibit Wnt Pathway for Oncology

SMYD-2BAY02


ZK-191784


ZK-216348

Drugs for Endometriosis and Uterine Fibroids
Recombinant Protein for Solid Tumors
Small Molecule to Inhibit Epigenetic Target for Oncology
Small Molecules for Cardiovascular Disease
Small Molecules for Oncology
Small Molecules to Inhibit GLUT1 and GLUT2
Small Molecule for Undisclosed Indication
Bayer AG - Pipeline Analysis
Bayer AG - Pipeline Products by Target
Bayer AG - Pipeline Products by Route of Administration
Bayer AG - Pipeline Products by Molecule Type
Bayer AG - Pipeline Products by Mechanism of Action
Bayer AG - Recent Pipeline Updates
Bayer AG - Dormant Projects
Bayer AG - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Bayer AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Bayer AG, Key Information
Bayer AG, Key Facts
Bayer AG - Pipeline by Indication, 2016
Bayer AG - Pipeline by Stage of Development, 2016
Bayer AG - Monotherapy Products in Pipeline, 2016
Bayer AG - Combination Treatment Modalities in Pipeline, 2016
Bayer AG - Partnered Products in Pipeline, 2016
Bayer AG - Partnered Products/ Combination Treatment Modalities, 2016
Bayer AG - Out-Licensed Products in Pipeline, 2016
Bayer AG - Out-Licensed Products/ Combination Treatment Modalities, 2016
Bayer AG - Pre-Registration, 2016
Bayer AG - Phase III, 2016
Bayer AG - Phase II, 2016
Bayer AG - Phase I, 2016
Bayer AG - Preclinical, 2016
Bayer AG - Discovery, 2016
Bayer AG - Unknown, 2016
Bayer AG - Pipeline by Target, 2016
Bayer AG - Pipeline by Route of Administration, 2016
Bayer AG - Pipeline by Molecule Type, 2016
Bayer AG - Pipeline Products by Mechanism of Action, 2016
Bayer AG - Recent Pipeline Updates, 2016
Bayer AG - Dormant Developmental Projects,2016
Bayer AG - Discontinued Pipeline Products, 2016
Bayer AG, Subsidiaries

LIST OF FIGURES

Bayer AG - Pipeline by Top 10 Indication, 2016
Bayer AG - Pipeline by Stage of Development, 2016
Bayer AG - Monotherapy Products in Pipeline, 2016
Bayer AG - Combination Treatment Modalities in Pipeline, 2016
Bayer AG - Partnered Products in Pipeline, 2016
Bayer AG - Out-Licensed Products in Pipeline, 2016
Bayer AG - Pipeline by Top 10 Target, 2016
Bayer AG - Pipeline by Top 10 Route of Administration, 2016
Bayer AG - Pipeline by Top 10 Molecule Type, 2016
Bayer AG - Pipeline Products by Top 10 Mechanism of Action, 2016
Skip to top


Oncodesign SA - Product Pipeline Review - 2015 US$ 1,200.00 Feb, 2015 · 24 pages
Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 58 pages
Fracture - Pipeline Review, H2 2014 US$ 1,500.00 Aug, 2014 · 73 pages
Chikungunya - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 90 pages

Ask Your Question

Bayer AG - Product Pipeline Review - 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: